113.93 -0.05 (-0.04%)
Pre-Market: 5:34AM EDT
|Bid||114.40 x 1300|
|Ask||115.03 x 800|
|Day's Range||112.98 - 117.26|
|52 Week Range||85.00 - 125.48|
|Beta (3Y Monthly)||1.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||138.13|
On 10 April 2019, the board of directors of Galapagos approved "Warrant Plan 2019 RMV," intended for the employees of its French subsidiary, Galapagos SASU, and "Warrant Plan 2019", intended mainly for the employees of the company and its subsidiaries, and for directors and an independent consultant of the company, within the framework of the authorized capital. Under these warrant plans, 2,070,000 warrants were created, subject to acceptances, and offered to the beneficiaries of the plans.
Analysts at UBS upgraded shares of Gilead Sciences Inc. to buy from neutral and boosted the price target on the stock to $77 from $75 on Wednesday, citing "two important clinical wins" that could each one day bring in more than $2 billion in revenue. "Following the failure of selonsertib in NASH, Gilead has rattled off two important clinical wins: positive Descovy PrEP data and filgotinib FINCH1/3 data," UBS analyst Carter Gould wrote in a note to clients. Descovy is currently approved to treat HIV, but it is not approved to be used as pre-exposure prophylaxis, or PrEP, to reduce the risk of acquiring the virus. Filgotinib is a promising investigational rheumatoid arthritis drug that Gilead is developing with Galapagos NV . "On the back of Biktarvy growth, Descovy PrEP utilization, and filgotinib, we have increased conviction that the top-line will grow and model faster growth," Gould wrote, adding he saw "less downside risk relative to peers (Amgen and Biogen)." He also raised his full-year EPS estimate for Gilead to $6.85 from $6.73, citing strong sales trends for HIV drugs Biktarvy and Truvada and lower projected SG&A expense due to the failure of selonsertib, an investigational drug designed to treat nonalcoholic steatohepatitis (NASH) that recently failed to meet the primary endpoint in a Phase 3 study. Shares of Gilead have gained 7.4% in the year to date, while the S&P 500 has gained 15%.
Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
Nomination of Mr. Peter Guenter for Galapagos' board of directors Mechelen, Belgium; 29 March 2019, 22.15 CET; regulated information - Galapagos NV (Euronext & NASDAQ:.
Shares of Belgium-based biotech Galapagos NV soared 23% on Friday after the company, together with pharmaceutical giant Gilead Sciences Inc., announced Thursday evening that two Phase 3 trials of their investigational rheumatoid arthritis drug had achieved their primary endpoints.
rose sharply Friday after the biotechnology company announced positive results for both doses of its rheumatoid arthritis drug, filgotinib, in Phase 3 trials. , showed patients improving more than a placebo in attaining an American College of Rheumatology 20% response, according to a company press release. The ACR20 is the baseline measure to evaluate rheumatoid arthritis treatments in clinical trials so that patients express a 20% improvement in at least three of five criteria determined by the ACR, according to the organization.
The two bioetchs said Phase 3 trial data for rheumatoid arthritis treatment filgotinib showed the drug met its primary endpoints and exhibited a safety profile consistent with previous research.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 28) Baxter International Inc (NYSE: BAX ) Constellation ...
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile -- Foster City,.
-- Filgotinib 100 mg and 200 mg Plus Methotrexate Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone --
-- Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior Inadequate Methotrexate Response --
-- Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone -- -- Filgotinib Safety Profile.
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile --
-- Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior.
NEW YORK, March 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 20) AstraZeneca plc (NYSE: AZN ) BioDelivery Sciences ...
Mechelen, Belgium; 20 March 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant.
Revenues doubled in 2018 Key 2018 clinical results: FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 6) Array Biopharma Inc (NASDAQ: ARRY ) Millendo Therapeutics ...
7 February 2019, 7.30 CET - Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809), and Galapagos NV (Euronext & NASDAQ: GLPG) today announced a global collaboration focused on a novel target for fibrosis and other indications. The collaboration concerns a small-molecule program, currently in pre-clinical drug development for the treatment of fibrotic diseases of the liver and other organs. The target has been identified and validated using Evotec's proprietary platforms for fibrotic diseases and NASH.
Mechelen, Belgium; 8 January 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Sands Capital.